




## CDAI clinical remission ITT-NRI, up to week 10

GLPG0634  
Clinical

% responders



\*\*: p&lt;0.01

13

Galápagos


Slide 13 of 25 ◀ ▶



## CDAI responses – TNF-failures (n=101) ITT-NRI, week 10

GLPG0634  
Clinical

% responders



18

Galápagos


Slide 18 of 25 ◀ ▶



## CDAI responses anti-TNF naives (n=73) ITT-NRI, week 10



% responders

**Galápagos**

16


Slide 16 of 25 ◀ ▶



## CDAI derived responses ITT-NRI, week 10



% responders




\*: p&lt;0.05; \*\*: p&lt;0.01

**Galápagos**

14

Slide 14 of 25 ◀ ▶



Slide Search Slides Downloads

**Baseline characteristics**  
Demographics & disease characteristics

This table compares baseline characteristics between the Placebo (N=44), 200 mg (N=130), and Total (N=174) groups.

	Placebo (N=44)	200 mg (N=130)	Total (N=174)
<b>Age, mean, years</b>	35.1	37.4	36.9
<b>Female</b>	59%	55%	56%
<b>Duration of CD, mean, years</b>	6.8	8.8	8.3
<b>CDAI, mean</b>	298.6	291.3	293.1
<b>Oral corticosteroids</b>	52%	48%	49%
<b>mean daily dose, mg/day</b>	23.6	23.1	23.2

11 Galápagos

Slide 11 of 25